Synergistic drug combinations tend to improve therapeutically relevant selectivity

Nature Biotechnology

Volumn 27, Issue 7, 2009, Pages 659-666

  Lehár, Joseph ^a,b   Krueger, Andrew S ^b   Avery, William ^a   Heilbut, Adrian M ^a   Johansen, Lisa M ^a   Price, E Roydon ^a   Rickles, Richard J ^a   Short III, Glenn F ^a   Staunton, Jane E ^a   Jin, Xiaowei ^a   Lee, Margaret S ^a   Zimmermann, Grant R ^a   Borisy, Alexis A ^a  

^a Department of Preclinical Development and Formulations   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-INFLAMMATORY; BACTERIAL METABOLISM; CELLULAR CONTEXTS; COMPLEX BIOLOGICAL SYSTEMS; DIFFERENTIAL EXPRESSIONS; DRUG COMBINATIONS; IN-CELL; LARGE SCALE SIMULATIONS; MULTITARGET; POTENTIAL DRUG; RAT MODEL; SIDE EFFECT; SINGLE-AGENT; SYNERGISTIC COMBINATIONS;

BIOLOGICAL SYSTEMS; CELL MEMBRANES;

DRUG INTERACTIONS;

2 MORPHOLINO 8 PHENYLCHROMONE; BENZAMIL; BUDESONIDE; CAMPTOTHECIN; CEPHARANTHINE; DEXAMETHASONE; DISULFIRAM; FORSKOLIN; MANGANESE SULFATE; METHYLDOPA; NORTRIPTYLINE; PACLITAXEL; PREDNISOLONE; RIBAVIRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; BACTERIAL METABOLISM; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; ESCHERICHIA COLI; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; SIMULATION;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; HUMANS; MALE; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS;

BACTERIA (MICROORGANISMS); RATTUS;

EID: 67650488269     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1549     Document Type: Article

References (49)

1. Hopkins, A.L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682-690 (2008).
2. Hughes, B. 2007 FDA drug approvals: a year of flux. Nat. Rev. Drug Discov. 7, 107-109 (2008).
3. Hartman, J.L.t, Garvik, B. & Hartwell, L. Principles for the buffering of genetic variation. Science 291, 1001-1004 (2001).
4. Stelling, J., Sauer, U., Szallasi, Z., Doyle, F.J. Ill & Doyle, J. Robustness of cellular functions. Cell 118, 675-685 (2004).
5. Kitano, H. A robustness-based approach to systems-oriented drug design. Nat. Rev. Drug Discov. 6, 202-210 (2007).
6. Kassouf, W. et al. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res. 65, 10524-10535 (2005).
7. Zarraga, I.G. & Schwarz, E.R. Coxibs and heart disease: what we have learned and what else we need to know. J. Am. Coil. Cardiol. 49, 1-14 (2007).
8. Sharom, J.R., Bellows, D.S. & Tyers, M. From large networks to small molecules. Curr. Opin. Chem. Biol. 8, 81-90 (2004).
9. Kaelin, W.G. Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5, 689-698 (2005).
10. Keith, C.T., Borisy, A.A. & Stockwell, B.R. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 4, 71-78 (2005).
11. Borisy, A.A. et al. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. USA 100, 7977-7982 (2003).
12. Yeh, P., Tschumi, A.I. & Kishony, R. Functional classification of drugs by properties of their pairwise interactions. Nat. Genet. 38, 489-494 (2006).
13. Boone, C., Bussey, H. & Andrews, B.J. Exploring genetic interactions and networks with yeast. Nat. Rev. Genet. 8, 437-449 (2007).
14. St. Onge, R.P. et al. Systematic pathway analysis using high-resolution fitness profiling of combinatorial gene deletions. Nat. Genet. 39, 199-206 (2007).
15. Hoon, S. et al. An integrated platform of genomic assays reveals small-molecule bioactivities. Nat. Chem. Biol. 4, 498-506 (2008).
16. Apsel, B. et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4, 691-699 (2008).
17. Araujo, R.P., Petricoin, E.F & Liotta, L.A. A mathematical model of combination therapy using the EGFR signaling network. Biosystems 80, 57-69 (2005).
18. Segre, D., Deluna, A., Church, G.M. & Kishony, R. Modular epistasis in yeast metabolism. Nat. Genet. 37, 77-83 (2005).
19. Yang, K., Bai, H., Ouyang, Q., Lai, L. & Tang, C. Finding multiple target optimal intervention in disease-related molecular network. Mol. Syst. Biol. 4, 228 (2008).
20. Radhakrishnan, M.L. & Tidor, B. Optimal drug cocktail design: methods for targeting molecular ensembles and insights from theoretical model systems. J. Chem. Inf. Model. 48, 1055-1073 (2008).
21. Zimmermann, G.R., Lehar, J. & Keith, C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 12, 34-42 (2007).
22. Greco, W.R., Bravo, G. & Parsons, J.C. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47, 331-385 (1995).
23. Tong, A.H. et al. Global mapping of the yeast genetic interaction network. Science 303, 808-813 (2004).
24. Lehår, J. et al. Chemical combination effects predict connectivity in biological systems. Mol. Syst. Biol. 3, 80 (2007).
25. Farr, M. & Bacon, P.A. How and when should combination therapy be used? The role of an anchor drug. Br. J. Rheumatol. 34, 100-103 (1995).
26. Berenbaum, M.C. What is synergy? Pharmacol. Rev. 41, 93-141 (1989).
27. Loewe, S. Die quantitativen Probleme der Pharmakologie. Ergeb. Physiol. 27, 47-187 (1928).
28. Bliss, C.I. The toxicity of poisons applied jointly. Ann. Appl. Biol. 26, 585-615 (1939).
29. Chou, T.C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55 (1984).
30. Press, W.H., Teukolsky, S.A., Vetterling, W.T. & Flannery, B.P Numerical Recipes in C: the Art of Scientific Computing, edn. 2, section 14.3.3 (Cambridge University Press, Cambridge, 1997).
31. Duarte, N.C., Herrgard, M.J. & Palsson, B.O. Reconstruction and validation of Saccharomyces cerevisiae iND750, a fully compartmentalized genome-scale metabolic model. Genome Res. 14, 1298-1309 (2004).
32. Edwards, J.S., Ibarra, R.U. & Palsson, B.O. In silico predictions of Escherichia coli metabolic capabilities are consistent with experimental data. Nat. Biotechnol. 19, 125-130 (2001).
33. Edwards, J.S. & Palsson, B.O. Metabolic flux balance analysis and the in silico analysis of Escherichia coli K-12 gene deletions. BMC Bioinformatics 1, 1 (2000).
34. Okamoto, M., Ono, M. & Baba, M. Potent inhibition of HIV type 1 replication by an antiinflammatory alkaloid, cepharanthine, in chronically infected monocytic cells. AIDS Res. Hum. Retroviruses 14, 1239-1245 (1998).
35. Kleyman, T.R. & Cragoe, E.J. Jr. Amiloride and its analogs as tools in the study of ion transport. J. Membr. Biol. 105, 1-21 (1988).
36. Virmani, R., Farb, A., Guagliumi, G. & Kolodgie, F.D. Drug-eluting stents: caution and concerns for long-term outcome. Coron. Artery Dis. 15, 313-318 (2004).
37. Tischler, J., Lehner, B. & Fraser, A.G. Evolutionary plasticity of genetic interaction networks. Nat. Genet. 40, 390-391 (2008).
38. Lehår, J., Krueger, A., Zimmermann, G. & Borisy, A. High-order combination effects and biological robustness. Mol. Syst. Biol. 4, 215 (2008).
39. Qiu, Y.H., Cheng, C., Dai, L. & Peng, Y.P. Effect of endogenous catecholamines in lymphocytes on lymphocyte function. J. Neuroimmunol. 167, 45-52 (2005).
40. Salicrú, A.N., Sams, C.F. & Marshall, G.D. Cooperative effects of corticosteroids and catecholamines upon immune deviation of the type-l/type-2 cytokine balance in favor of type-2 expression in human peripheral blood mononuclear cells. Brain Behav. Immun. 21, 913-920 (2007).
41. Su, A.I. et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl. Acad. Sci. USA 101, 6062-6067 (2004).
42. Schacke, H., Docke, W.D. & Asadullah, K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96, 23-43 (2002).
43. Kvien, T.K. et al. Efficacy and safety of a novel synergistic drug candidate, CRx-102, in hand osteoarthritis. Ann. Rheum. Dis. 67, 942-948 (2007).
44. Zimmermann, G.R. et al. Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. Arthritis Res. Ther. 11, R12 (2009).
45. Schäcke, H., Rehwinkel, H. & Asadullah, K. Dissociated glucocorticoid receptor ligands: compounds with an improved therapeutic index. Curr. Opin. Investig. Drugs 6, 503-507 (2005).
46. Keasling, J.D. Synthetic biology for synthetic chemistry. ACS Chem. Biol. 3, 64-76 (2008).
47. Holm, S. A simple sequential rejective multiple test procedure. Scand. J. Stat. 6, 65-70 (1979).
48. Filliben, JJ. in Engineering Statistics Handbook, vol. 2007 (National Institute of Standards and Technology, Gaithersburg, MD, 2005) http://www.itl.nist.gov/div898/handbook/eda/section3/eda356.htm.
49. Berenbaum, M.C. The expected effect of a combination of agents: the general solution. J. Theor. Biol. 114, 413-431 (1985).